Skip to content

CG Oncology CGON Enterprise value

Enterprise value at other companies

Pfizer logo
PfizerPFE
$222.4B+9.2%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$622.06B+50.5%
Gilead Sciences logo
Gilead SciencesGILD
$187.53B+19.7%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
$8.16B+187%
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
$6.02B+951%
Tango Therapeutics logo
Tango TherapeuticsTNGX
$2.86B+2,204%

Other financials

Income statement

See full
Revenue$1.1M+1,983%
Operating income-$66.4M-57.3%
Net income-$60.2M-74.7%
EPS (diluted)-$0.71-57.8%

Balance sheet

See full
Cash & equivalents$33.7M-18.7%
Total debt$7.6M+631%
Total equity$1.1B+54.9%
Total assets$1.1B+55.9%

Cash flow

See full
Operating cash flow-$56.9M-94.5%
CapEx$304.0K+1,800%
Free cash flow-$57.2M-95.4%

Valuation

See full
Market cap$5.39B+206%

Profitability

See full
Operating margin-4,239%-1,872pp
Net margin-3,682.6%-1,601pp
FCF margin-3,163.8%-1,351pp

Returns & leverage

See full
Return on equity-20.8%+7.1pp
Debt / equity0.0×
Current ratio31.3×+0.3×

Where this comes from

Calculated from CG Oncology’s reported figures.

The official record: CG Oncology’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about CG Oncology's enterprise value.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CG Oncology's enterprise value?
CG Oncology (CGON) reported enterprise value of $5.69B in Q1 2026.
How has CG Oncology's enterprise value changed year-over-year?
CG Oncology's enterprise value increased by 211.5% year-over-year, from $1.83B to $5.69B.
What does enterprise value mean?
Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.